Prilenia Therapeutics is a clinical-stage biotech company dedicated to developing novel therapeutics aimed at slowing the progression of neurodegenerative diseases and neurodevelopmental disorders. Their lead product candidate, pridopidine, has received Orphan Drug Designation in Huntington's disease and Amyotrophic Lateral Sclerosis in both the U.S. and Europe, as well as Fast Track designation from the FDA for Huntington’s disease. Prilenia is actively preparing for potential regulatory filings and advancing to global phase 3 clinical trials. The company operates in a flexible and dynamic environment, emphasizing teamwork and collaboration to make a positive impact on the lives of patients and their families. Prilenia's mission extends to exploring the potential of pridopidine’s novel mechanism as a Sigma-1 receptor agonist in treating various other neurological conditions.